Physician profile
Steven A Swaldi
NPI 1639150535
$8,108.45
in general payments reported to CMS, 2019-2025
52 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,670 · 2020: $922 · 2021: $1,025 · 2022: $1,591 · 2023: $1,389 · 2024: $1,001 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.23 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,185.72 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $806.15 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $539.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $492.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $399.70 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Astellas Pharma US INC | $385.90 | 2022-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $316.17 | 2019-2020 | |
| Novo Nordisk INC | $285.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bausch Health US, LLC | $279.66 | 2019-2025 | Wellbutrin, Aplenzin |
| Biohaven Pharmaceutical Holding Company LTD. | $272.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.86 | 2021-2025 | Jardiance, Glyxambi, Tradjenta |
| Amgen INC. | $217.35 | 2019-2025 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.41 | 2019-2024 | Xifaxan, Trulance |
| Antares Pharma, INC. | $183.68 | 2019-2025 | Xyosted |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Swaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.